Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ex-US FDA Director John Jenkins Sketches Regulatory Path For Esperion's Bempedoic Acid

Executive Summary

Imbalance in deaths in study of novel cholesterol drug has been a concern, but Esperion made the case for safety during a July 10 investor day, which featured presentations by ex-FDA director John Jenkins and Cleveland Clinic cardiologist Steve Nissen.

Advertisement

Related Content

PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case
Deaths In Esperion's Long-Term Bempedoic Acid Trial Spur Fears Of Commercial Delay
US Office Of New Drugs Revamp Taking Shape: More Review Divisions Coming, But Who Will Lead Them?
PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent
Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews
Esperion Expects Speedy Regulatory Path For Bempedoic Acid/Zetia Combo
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel